Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

Literature DB >> 34662193

Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

S Baklouti^1,2, S Marolleau², P Chavanet³, E Bonnet⁴, D Concordet², P Gandia^1,2.

Abstract

Entities: Chemical

Keywords: dalbavancin; drug dosing adjustment; osteoarticular infections; total concentrations

Mesh：

Substances：

Year: 2021 PMID： 34662193 PMCID： PMC8765300 DOI： 10.1128/AAC.01493-21

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.938

Keyword Cloud
References

× No keyword cloud information.

7 in total

Review 1. Changes in plasma protein binding have little clinical relevance.

Authors: Leslie Z Benet; Betty-ann Hoener
Journal: Clin Pharmacol Ther Date: 2002-03 Impact factor: 6.875

2. Free drug fraction vs free drug concentration: a matter of frequent confusion.

Authors: P L Toutain; A Bousquet-Melou
Journal: J Vet Pharmacol Ther Date: 2002-12 Impact factor: 1.786

Review 3. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.

Authors: Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal: Infect Dis (Lond) Date: 2017-03-06

4. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

Authors: Pier Giorgio Cojutti; Matteo Rinaldi; Eleonora Zamparini; Nicolò Rossi; Sara Tedeschi; Matteo Conti; Federico Pea; Pierluigi Viale
Journal: Antimicrob Agents Chemother Date: 2021-03-01 Impact factor: 5.191

Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

Review 1. Changes in plasma protein binding have little clinical relevance.

2. Free drug fraction vs free drug concentration: a matter of frequent confusion.

Review 3. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.

4. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

5. Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Review 6. Plasma protein binding displacement interactions--why are they still regarded as clinically important?

7. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.